ABCG2 p.Cys592Ser

Predicted by SNAP2: A: D (66%), D: D (80%), E: D (80%), F: D (80%), G: D (80%), H: D (80%), I: D (71%), K: D (85%), L: D (75%), M: D (80%), N: D (80%), P: D (85%), Q: D (80%), R: D (85%), S: D (75%), T: D (59%), V: D (75%), W: D (80%), Y: D (66%),
Predicted by PROVEAN: A: D, D: D, E: D, F: D, G: D, H: D, I: D, K: D, L: D, M: D, N: D, P: D, Q: D, R: D, S: D, T: D, V: D, W: D, Y: D,

[switch to compact view]
Comments [show]
Publications
[hide] Kage K, Fujita T, Sugimoto Y
Role of Cys-603 in dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2.
Cancer Sci. 2005 Dec;96(12):866-72., [PMID:16367905] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Ozvegy-Laczka C, Laczko R, Hegedus C, Litman T, Varady G, Goda K, Hegedus T, Dokholyan NV, Sorrentino BP, Varadi A, Sarkadi B
Interaction with the 5D3 monoclonal antibody is regulated by intramolecular rearrangements but not by covalent dimer formation of the human ABCG2 multidrug transporter.
J Biol Chem. 2008 Sep 19;283(38):26059-70. Epub 2008 Jul 21., 2008-09-19 [PMID:18644784] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Shigeta J, Katayama K, Mitsuhashi J, Noguchi K, Sugimoto Y
BCRP/ABCG2 confers anticancer drug resistance without covalent dimerization.
Cancer Sci. 2010 Aug;101(8):1813-21. Epub 2010 Apr 28., [PMID:20518788] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Ni Z, Bikadi Z, Rosenberg MF, Mao Q
Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).
Curr Drug Metab. 2010 Sep;11(7):603-17., [PMID:20812902] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Szafraniec MJ, Szczygiel M, Urbanska K, Fiedor L
Determinants of the activity and substrate recognition of breast cancer resistance protein (ABCG2).
Drug Metab Rev. 2014 Nov;46(4):459-74. doi: 10.3109/03602532.2014.942037. Epub 2014 Jul 18., [PMID:25036722] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]